FDA Spells Out Details Of Premarket Clinical Trial Inspections
This article was originally published in The Gray Sheet
A final guidance document released by FDA Jan. 8 gives the timetable that device makers can expect when PMA applications and supplements are reviewed by the device center's bioresearch monitoring division
You may also be interested in...
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
A new draft 1guidance explains CDRH's process for ensuring the integrity of data included in device premarket approval submissions
New tendering rules in Belgium aim to improve competition between biosimilars and originators, for example by setting contract durations for tendering contracts and limiting the criteria for such contracts.